Shares of Cara Therapeutics (NASDAQ: CARA) rose by as much as 22% in pre-market trading today on light volume. The spark?Cara's shares are responding positively to the news that the biotech signed an ex-U.S. licensing deal with Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP) for Korsuva (CR-845). Korsuva is an experimental drug being assessed as a breakthrough treatment for chronic pruritus (itching) in dialysis patients with advanced kidney disease. Image Source: Getty Images.Continue reading